Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: Meta-analysis of randomised controlled trials

BMJ (Online)

Volumn 365, Issue , 2019, Pages

  Musso, Giovanni ^a   Gambino, Roberto ^b   Cassader, Maurizio ^b   Paschetta, Elena ^a  

^a HUMANITAS UNIVERSITY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLYCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ALBUMINURIA; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT LOSS; CLINICAL ASSESSMENT; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FASTING; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ANALYSIS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCATED HEMOGLOBIN A; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85064393237     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.l1328     Document Type: Article

References (73)

1. US Center for Disease Control and Prevention. 2019. https://www.cdc.gov/diabetes/library/socialmedia/infographics.html.
2. Turner R, Stratton I, Horton V, et al., UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350: 1288-93. doi: 10.1016/S0140-6736(97)03062-6
3. Miller KM, Foster NC, Beck RW, et al., T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38: 971-8. doi: 10.2337/dc15-0078
4. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972-82. doi: 10.1056/NEJMoa1408214
5. Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37: 9-16. doi: 10.2337/dc13-2112
6. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018. Diabetes Care 2018; 41 (Suppl 1): S73-85. doi: 10.2337/dc18-S008
7. Gerstein HC, Miller ME, Byington RP, et al., Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59. doi: 10.1056/NEJMoa0802743
8. Zoungas S, Patel A, Chalmers J, et al., ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-8. doi: 10.1056/NEJMoa1003795
9. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-95. doi: 10.2337/dc12-2480
10. Cefalu WT, Tamborlane WV, Skyler JS. Type 1 diabetes at a crossroads! Diabetes Care 2015; 38: 968-70. doi: 10.2337/dc15-0615
11. Monnier L, Colette C, Owens D. The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 2012; 95: 303-11. doi: 10.1016/j.diabres.2011.10.014
12. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54. doi: 10.2337/db08-0063
13. Šoupal J, Škrha J Jr, Fajmon M, et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014; 16: 198-203. doi: 10.1089/dia.2013.0205
14. Snell-Bergeon JK, Roman R, Rodbard D, et al. Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med 2010; 27: 1436-42. doi: 10.1111/j.1464-5491.2010.03127.x
15. Zinman B, Marso SP, Poulter NR, et al., DEVOTE Study Group. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia 2018; 61: 48-57. doi: 10.1007/s00125-017-4423-z
16. Pieber TR, Marso SP, McGuire DK, et al., DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018; 61: 58-65. doi: 10.1007/s00125-017-4422-0
17. Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther 2017; 19 (S2): S16-26. doi: 10.1089/dia.2017.0029
18. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631-40. doi: 10.2337/dc17-1600
19. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669-701. doi: 10.2337/dci18-0033
20. American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes-2018. Diabetes Care 2018; 41 (Suppl 1): S55-64. doi: 10.2337/dc18-S006
21. Seidelmann SB, Feofanova E, Yu B, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol 2018; 72: 1763-73. doi: 10.1016/j.jacc.2018.07.061
22. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018; 20: 1755-61. doi: 10.1111/dom.13260
23. Powell DR, DaCosta CM, Smith M, et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther 2014; 350: 232-42. doi: 10.1124/jpet.114.214304
24. Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 2013; 345: 250-9. doi: 10.1124/jpet.113.203364
25. Meek TH, Dorfman MD, Matsen ME, et al. Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes 2015; 64: 2376-87. doi: 10.2337/db14-1562
26. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38: 1181-8. doi: 10.2337/dc14-2806
27. Bode B, Banks P, Strumph P, Sawhney S. The Sotagliflozin JDRF Study Writing Group. Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study). Diabetologia 2017; 60: S87-8.
28. Baker C, Wason S, Banks P. A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4). Diabetologia 2017; 60: S409.
29. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377: 2337-48. doi: 10.1056/NEJMoa1708337
30. Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. Diabetes Care 2018; 41: 1970-80. doi: 10.2337/dc18-0343.
31. 1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study. Diabetes Care 2018; 41: 1981-90. doi: 10.2337/dc18-0342.
32. US Food and Drug Administration. Search results for sotagliflozin. https://search.usa.gov/search?utf8=%E2%9C%93&affiliate=fda&query=sotagliflozin&commit=Search
33. European Medicines Agency. Search results for sotagliflozin. https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=sotagliflozin
34. Pharmaceutical and Medical Devices Agency. Search results for sotagliflozin. https://ss.pmda.go.jp/en_all/search.x?q=sotagliflozin&ie=UTF-8&page=1&x=30&y=11
35. Lexicon Pharmaceuticals. Homepage. 2019. www.lexpharma.com
36. Sanofi. Homepage. 2019. https://www.sanofi.com
37. Esposito K, Giugliano D, Nappo F, Marfella R, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-9. doi: 10.1161/01.CIR.0000134501.57864.66
38. Raz I, Ceriello A, Wilson PW, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 2011; 34: 1511-3. doi: 10.2337/dc10-2375
39. US Food and Drug Administration. FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611454.htm
40. Baghurst PA. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther 2011; 13: 296-302. doi: 10.1089/dia.2010.0090
41. Medical dictionary for regulatory activities. Homepage. https://www.meddra.org/. Accessed 21 July 2018.
42. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.2.0. Cochrane Collaboration, updated March 2011. 14 July 2017. https://community.cochrane.org/editorial-and-publishing-policy-resource/cochrane-review-development/cochrane-handbooks/cochrane-handbook-systematic-reviews-interventions
43. Viswanathan M, Patnode CD, Berkman ND, et al. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J Clin Epidemiol 2018; 97: 26-34. doi: 10.1016/j.jclinepi.2017.12.004
44. Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials 2016; 13: 161-8. doi: 10.1177/1740774515602688
45. Lexchin J. Sponsorship bias in clinical research. Int J Risk Saf Med 2012; 24: 233-42.
46. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190: 583-92. doi: 10.1097/00005053-200209000-00002
47. National Research Council. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. The prevention and treatment of missing data in clinical trials. National Academies Press, 2010.
48. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008; 299: 1813-7. doi: 10.1001/jama.299.15.1813
49. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005; 182: 557-60.
50. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. JAMA 2006; 295: 1645-6. doi: 10.1001/jama.295.14.1645
51. Manager R. (RevMan). Version 5.3. Copenhagen, Denmark: Nordic Cochrane Center, Cochrane Collaboration; 2012. https://community.cochrane.org/help/tools-and-software/revman-5
52. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. doi: 10.1136/bmj.b2700
53. Guyatt GH, Oxman AD, Kunz R, et al., GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011; 64: 1294-302. doi: 10.1016/j.jclinepi.2011.03.017
54. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77. doi: 10.1002/sim.2528
55. Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ 2017; 356: j573. doi: 10.1136/bmj.j573
56. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94. doi: 10.1016/j.jclinepi.2010.04.026
57. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011; 64: 1283-93. doi: 10.1016/j.jclinepi.2011.01.012
58. European Association for the Study of Diabetes. Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study). EASD virtual meeting, oral presentation 186. 2017. https://www.easd.org/virtualmeeting/home.html#!resources/efficacy-and-safety-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-to-insulin-in-young-adults-with-poorly-controlled-type-1-diabetes-jdrf-study-15ae18d4-b8f6-439c-87ea-2f19dcad388e
59. European Association for the Study of Diabetes. A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4). EASD virtual meeting, ePoster 186. 2017. https://www.easd.org/virtualmeeting/home.html#!resources/a-12-week-dose-ranging-study-of-sotagliflozin-a-dual-sglt1-and-sglt2-inhibitor-as-adjunct-therapy-to-insulin-in-type-1-diabetes-intandem4-eac92dc0-58bd-48ae-9cba-aa1675a947cf
60. Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 2018; 41: 104-11. doi: 10.2337/dc17-1669
61. NovoNordisk. Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211). Company announcement 51/2015. https://www.novonordisk.com/bin/getPDF.1947182.pdf. Accessed 24 October 2018.
62. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-93. doi: 10.3109/07853890.2011.560181
63. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 2017; 40: 832-8. doi: 10.2337/dc16-1769
64. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683-9. doi: 10.2337/diab.42.11.1683
65. Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 2018; 138: 1537-50. doi: 10.1161/CIRCULATIONAHA.118.035901
66. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752-72. doi: 10.1161/CIRCULATIONAHA.116.021887
67. Janssen Research & Development. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. 11 December 2012. www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf (accessed 13 September 2014).
68. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014; 3: 212262.
69. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638-42. doi: 10.2337/dc15-1380
70. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 2017; 19: 814-21. doi: 10.1111/dom.12882
71. Olsen SE, Asvold BO, Frier BM, Aune SE, Hansen LI, Bjørgaas MR. Hypoglycaemia symptoms and impaired awareness of hypoglycaemia in adults with Type 1 diabetes: the association with diabetes duration. Diabet Med 2014; 31: 1210-7. doi: 10.1111/dme.12496
72. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687-93. doi: 10.2337/dc15-0843
73. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [correction: Lancet Diabetes Endocrinol 2017;5:864-76]. Lancet Diabetes Endocrinol 2017; 5: 864-76.